<p>2025 年 11 月 24 日- 下午 06:39</p>
<p>纽约，2025 年 11 月 24 日（GLOBE NEWSWIRE）-- Mesoblast Limited（纳斯达克代码：MESO；澳大利亚证券交易所代码：MSB），全球领先的用于治疗炎症疾病的异体细胞药物的公司，今天在首席执行官的年度股东大会（AGM）讲话中提供了交易更新以及全面的运营概述。</p>
<p>截至 2025 年 12 月 31 日的季度，管理层预计 Ryoncil®（remestemcel-L-rknd）的销售收入将超过 3000 万美元。这比截至 2025 年 9 月 30 日的前一个季度的 2190 万美元的销售收入增长了超过 37%。</p>
<p><strong>关于 Mesoblast</strong></p>
<p>Mesoblast（公司）是开发异体（现成）细胞药物以治疗严重和危及生命的炎症疾病的全球领导者。公司的专有间充质谱系细胞治疗技术平台的疗法通过释放抗炎因子来应对严重炎症，这些因子对免疫系统的多个效应臂进行反制和调节，从而显著减少有害的炎症过程。</p>
<p>Mesoblast 的 Ryoncil®（remestemcel-L-rknd）用于治疗 2 个月及以上儿童患者的类固醇难治性急性移植物抗宿主病（SR-aGvHD），是首个获得 FDA 批准的间充质基质细胞（MSC）疗法。请参见 www.ryoncil.com 上的完整处方信息。</p>
<p>Mesoblast 致力于基于其 remestemcel-L 和 rexlemestrocel-L 异体基质细胞技术平台开发针对不同适应症的额外细胞疗法。Ryoncil®正在开发用于包括成人 SR-aGvHD 和生物药物耐药性炎症性肠病在内的其他炎症疾病。Rexlemestrocel-L 正在开发用于心力衰竭和慢性下背痛。公司已在日本、欧洲和中国建立了商业合作伙伴关系。</p>
<p><strong>关于 Mesoblast 的知识产权：</strong> Mesoblast 拥有强大而广泛的全球知识产权组合，拥有超过 1000 项已授予的专利或专利申请，涵盖间充质基质细胞的物质组成、制造方法和适应症。这些已授予的专利和专利申请提供了商业保护，延续至至少 2044 年，覆盖所有主要市场。</p>
<p><strong>关于 Mesoblast 的制造：</strong> 公司的专有制造工艺能够生产工业规模的、冷冻保存的、现成的细胞药物。这些细胞疗法具有明确的药品释放标准，计划在全球范围内为患者提供。</p>
<p>Mesoblast 在澳大利亚、美国和新加坡设有办事处，并在澳大利亚证券交易所（MSB）和纳斯达克（MESO）上市。有关更多信息，请访问 www.mesoblast.com，LinkedIn: Mesoblast Limited 和 X: @Mesoblast</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含与未来事件或我们未来财务表现相关的前瞻性声明和预测，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。我们根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的安全港条款作出此类前瞻性声明。前瞻性声明不应被视为对未来表现或结果的保证，实际结果可能与这些前瞻性声明中预期的结果不同，而这种差异可能是重大且不利的。前瞻性声明包括但不限于关于：Mesoblast 的临床前和临床研究的启动、时间、进展和结果，以及 Mesoblast 的研究和开发项目；Mesoblast 将产品候选者推进、招募并成功完成临床研究（包括多国临床试验）的能力；Mesoblast 提升其制造能力的能力；监管申请和批准、制造活动和产品营销活动的时间或可能性（如有）；Mesoblast 的 RYONCIL 用于儿童 SR-aGVHD 的商业化及任何其他产品候选者（如获批准）；围绕干细胞治疗的监管或公众认知及市场接受度；Mesoblast 的产品候选者（如有获批准）因患者不良事件或死亡而可能被撤回市场的潜在性；战略合作协议的潜在利益及 Mesoblast 进入和维持已建立的战略合作的能力；Mesoblast 在其产品候选者上建立和维持知识产权的能力，以及在涉嫌侵权的情况下成功捍卫这些权利的能力；Mesoblast 能够为其产品候选者和技术建立和维持的知识产权保护范围；Mesoblast 的费用、未来收入、资本需求及其对额外融资的需求的估计；Mesoblast 的财务表现；与 Mesoblast 的竞争对手和行业相关的发展；以及 Mesoblast 的产品候选者（如获批准）的定价和报销。您应将本新闻稿与我们最近提交给 SEC 的报告或我们网站上的风险因素一起阅读。可能导致 Mesoblast 的实际结果、表现或成就与这些声明所表达或暗示的结果存在重大差异的不确定性和风险，因此，您不应对这些前瞻性声明过度依赖。除法律或 ASX 上市规则要求外，我们不承担任何公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。本公告中提供的过去表现仅供参考，不应被视为（也不是）未来表现的指示。</p>
<p><strong>非金融产品建议</strong></p>
<p>本公告不构成金融产品建议或投资建议（也不构成税务、会计或法律建议），并且在准备时未考虑个人的目标、财务状况或需求。在做出投资决策之前，潜在投资者应考虑该信息的适当性，考虑到他们自己的目标、财务状况和需求，并寻求适当的专业建议。</p>
<p><strong>免责声明</strong></p>
<p>在法律允许的最大范围内，Mesoblast 及其董事、高级职员、员工、顾问和代理人否认任何发布更新或修订信息以反映任何期望或假设变化的义务或承诺，并对这些前瞻性声明（包括但不限于因疏忽而产生的任何责任）不承担任何责任。</p>
<p>发布由首席执行官授权。</p>
<p><em>如需更多信息，请联系：</em></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><em>企业传播 / 投资者</em></strong></td>
<td></td>
</tr>
<tr>
<td>Paul Hughes</td>
<td></td>
</tr>
<tr>
<td>T: +61 3 9639 6036</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>媒体 – 全球</em></strong></td>
<td></td>
</tr>
<tr>
<td>Allison Worldwide</td>
<td></td>
</tr>
<tr>
<td>Emma Neal</td>
<td></td>
</tr>
<tr>
<td>T: +1 603 545 4843</td>
<td></td>
</tr>
<tr>
<td>E: emma.neal@allisonworldwide.com</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>媒体 – 澳大利亚</em></strong></td>
<td></td>
</tr>
<tr>
<td>BlueDot Media</td>
<td></td>
</tr>
<tr>
<td>Steve Dabkowski</td>
<td></td>
</tr>
<tr>
<td>T: +61 419 880 486</td>
<td></td>
</tr>
<tr>
<td>E: steve@bluedot.net.au</td>
<td></td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU1UY3pOQ00zTWpreE1qQTJJekl3TVRjME16ST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU1UY3pOQ00zTWpreE1qQTJJekl3TVRjME16ST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTNjOWI5NmYtZWMxOC00MjMxLTg2ZjMtODY0ZGM2MDNhZjQyLTEwMjkwMDUtMjAyNS0xMS0yNC1lbg==/tiny/Mesoblast-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTNjOWI5NmYtZWMxOC00MjMxLTg2ZjMtODY0ZGM2MDNhZjQyLTEwMjkwMDUtMjAyNS0xMS0yNC1lbg==/tiny/Mesoblast-Limited.png"/></p>

MESO

<p>Mesoblast Limited 在其年度股东大会上报告了强劲的财务表现，预计截至 2025 年 12 月 31 日的季度，Ryoncil® 销售的总收入将超过 3000 万美元，比上一季度增长 37%。作为同种异体细胞药物的领导者，该公司继续扩展其产品线，并保持强大的知识产权组合。前瞻性声明强调了未来财务表现和产品开发中的潜在风险和不确定性</p>

<p>11/24/2025 - 06:39 PM</p>
<div class="lb-trans"><p>2025 年 11 月 24 日- 下午 06:39</p>
</div><p>NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive’s Annual General Meeting (AGM) address.</p>
<div class="lb-trans"><p>纽约，2025 年 11 月 24 日（GLOBE NEWSWIRE）-- Mesoblast Limited（纳斯达克代码：MESO；澳大利亚证券交易所代码：MSB），全球领先的用于治疗炎症疾病的异体细胞药物的公司，今天在首席执行官的年度股东大会（AGM）讲话中提供了交易更新以及全面的运营概述。</p>
</div><p>For the quarter ending December 31, 2025, management expects gross revenue of more than US$30.0 million from sales of Ryoncil® (remestemcel-L-rknd). This represents more than 37% increase on the US$21.9 million in gross revenue from Ryoncil® in the prior quarter ended September 30, 2025.</p>
<div class="lb-trans"><p>截至 2025 年 12 月 31 日的季度，管理层预计 Ryoncil®（remestemcel-L-rknd）的销售收入将超过 3000 万美元。这比截至 2025 年 9 月 30 日的前一个季度的 2190 万美元的销售收入增长了超过 37%。</p>
</div><p><strong>About Mesoblast</strong></p>
<div class="lb-trans"><p><strong>关于 Mesoblast</strong></p>
</div><p>Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.</p>
<div class="lb-trans"><p>Mesoblast（公司）是开发异体（现成）细胞药物以治疗严重和危及生命的炎症疾病的全球领导者。公司的专有间充质谱系细胞治疗技术平台的疗法通过释放抗炎因子来应对严重炎症，这些因子对免疫系统的多个效应臂进行反制和调节，从而显著减少有害的炎症过程。</p>
</div><p>Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.</p>
<div class="lb-trans"><p>Mesoblast 的 Ryoncil®（remestemcel-L-rknd）用于治疗 2 个月及以上儿童患者的类固醇难治性急性移植物抗宿主病（SR-aGvHD），是首个获得 FDA 批准的间充质基质细胞（MSC）疗法。请参见 www.ryoncil.com 上的完整处方信息。</p>
</div><p>Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.</p>
<div class="lb-trans"><p>Mesoblast 致力于基于其 remestemcel-L 和 rexlemestrocel-L 异体基质细胞技术平台开发针对不同适应症的额外细胞疗法。Ryoncil®正在开发用于包括成人 SR-aGvHD 和生物药物耐药性炎症性肠病在内的其他炎症疾病。Rexlemestrocel-L 正在开发用于心力衰竭和慢性下背痛。公司已在日本、欧洲和中国建立了商业合作伙伴关系。</p>
</div><p><strong>About Mesoblast intellectual property:</strong> Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.</p>
<div class="lb-trans"><p><strong>关于 Mesoblast 的知识产权：</strong> Mesoblast 拥有强大而广泛的全球知识产权组合，拥有超过 1000 项已授予的专利或专利申请，涵盖间充质基质细胞的物质组成、制造方法和适应症。这些已授予的专利和专利申请提供了商业保护，延续至至少 2044 年，覆盖所有主要市场。</p>
</div><p><strong>About Mesoblast manufacturing:</strong> The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.</p>
<div class="lb-trans"><p><strong>关于 Mesoblast 的制造：</strong> 公司的专有制造工艺能够生产工业规模的、冷冻保存的、现成的细胞药物。这些细胞疗法具有明确的药品释放标准，计划在全球范围内为患者提供。</p>
</div><p>Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast</p>
<div class="lb-trans"><p>Mesoblast 在澳大利亚、美国和新加坡设有办事处，并在澳大利亚证券交易所（MSB）和纳斯达克（MESO）上市。有关更多信息，请访问 www.mesoblast.com，LinkedIn: Mesoblast Limited 和 X: @Mesoblast</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except where required by law or the ASX Listing Rules. Past performance given in this announcement is given for illustrative purposes only and should not be relied on as (and is not) an indication of future performance.</p>
<div class="lb-trans"><p>本新闻稿包含与未来事件或我们未来财务表现相关的前瞻性声明和预测，并涉及已知和未知的风险、不确定性及其他因素，这些因素可能导致我们的实际结果、活动水平、表现或成就与这些前瞻性声明所表达或暗示的任何未来结果、活动水平、表现或成就存在重大差异。我们根据 1995 年《私人证券诉讼改革法案》和其他联邦证券法的安全港条款作出此类前瞻性声明。前瞻性声明不应被视为对未来表现或结果的保证，实际结果可能与这些前瞻性声明中预期的结果不同，而这种差异可能是重大且不利的。前瞻性声明包括但不限于关于：Mesoblast 的临床前和临床研究的启动、时间、进展和结果，以及 Mesoblast 的研究和开发项目；Mesoblast 将产品候选者推进、招募并成功完成临床研究（包括多国临床试验）的能力；Mesoblast 提升其制造能力的能力；监管申请和批准、制造活动和产品营销活动的时间或可能性（如有）；Mesoblast 的 RYONCIL 用于儿童 SR-aGVHD 的商业化及任何其他产品候选者（如获批准）；围绕干细胞治疗的监管或公众认知及市场接受度；Mesoblast 的产品候选者（如有获批准）因患者不良事件或死亡而可能被撤回市场的潜在性；战略合作协议的潜在利益及 Mesoblast 进入和维持已建立的战略合作的能力；Mesoblast 在其产品候选者上建立和维持知识产权的能力，以及在涉嫌侵权的情况下成功捍卫这些权利的能力；Mesoblast 能够为其产品候选者和技术建立和维持的知识产权保护范围；Mesoblast 的费用、未来收入、资本需求及其对额外融资的需求的估计；Mesoblast 的财务表现；与 Mesoblast 的竞争对手和行业相关的发展；以及 Mesoblast 的产品候选者（如获批准）的定价和报销。您应将本新闻稿与我们最近提交给 SEC 的报告或我们网站上的风险因素一起阅读。可能导致 Mesoblast 的实际结果、表现或成就与这些声明所表达或暗示的结果存在重大差异的不确定性和风险，因此，您不应对这些前瞻性声明过度依赖。除法律或 ASX 上市规则要求外，我们不承担任何公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。本公告中提供的过去表现仅供参考，不应被视为（也不是）未来表现的指示。</p>
</div><p><strong>Not financial product advice</strong></p>
<div class="lb-trans"><p><strong>非金融产品建议</strong></p>
</div><p>This announcement does not constitute financial product advice or investment advice (nor tax, accounting or legal advice) and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate professional advice.</p>
<div class="lb-trans"><p>本公告不构成金融产品建议或投资建议（也不构成税务、会计或法律建议），并且在准备时未考虑个人的目标、财务状况或需求。在做出投资决策之前，潜在投资者应考虑该信息的适当性，考虑到他们自己的目标、财务状况和需求，并寻求适当的专业建议。</p>
</div><p><strong>Disclaimer</strong></p>
<div class="lb-trans"><p><strong>免责声明</strong></p>
</div><p>To the maximum extent permitted by law, Mesoblast and its directors, officers, employees, advisers and agents disclaim any obligation or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions, and disclaim all responsibility and liability for these forward-looking statements (including, without limitation, any liability for negligence).</p>
<div class="lb-trans"><p>在法律允许的最大范围内，Mesoblast 及其董事、高级职员、员工、顾问和代理人否认任何发布更新或修订信息以反映任何期望或假设变化的义务或承诺，并对这些前瞻性声明（包括但不限于因疏忽而产生的任何责任）不承担任何责任。</p>
</div><p>Release authorizedby the Chief Executive.</p>
<div class="lb-trans"><p>发布由首席执行官授权。</p>
</div><p><em>For more information, please contact:</em></p>
<div class="lb-trans"><p><em>如需更多信息，请联系：</em></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><em>Corporate Communications / Investors</em></strong></td>
<td></td>
</tr>
<tr>
<td>Paul Hughes</td>
<td></td>
</tr>
<tr>
<td>T: +61 3 9639 6036</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>Media – Global</em></strong></td>
<td></td>
</tr>
<tr>
<td>Allison Worldwide</td>
<td></td>
</tr>
<tr>
<td>Emma Neal</td>
<td></td>
</tr>
<tr>
<td>T: +1 603 545 4843</td>
<td></td>
</tr>
<tr>
<td>E: emma.neal@allisonworldwide.com</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>Media – Australia</em></strong></td>
<td></td>
</tr>
<tr>
<td>BlueDot Media</td>
<td></td>
</tr>
<tr>
<td>Steve Dabkowski</td>
<td></td>
</tr>
<tr>
<td>T: +61 419 880 486</td>
<td></td>
</tr>
<tr>
<td>E: steve@bluedot.net.au</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><em>企业传播 / 投资者</em></strong></td>
<td></td>
</tr>
<tr>
<td>Paul Hughes</td>
<td></td>
</tr>
<tr>
<td>T: +61 3 9639 6036</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>媒体 – 全球</em></strong></td>
<td></td>
</tr>
<tr>
<td>Allison Worldwide</td>
<td></td>
</tr>
<tr>
<td>Emma Neal</td>
<td></td>
</tr>
<tr>
<td>T: +1 603 545 4843</td>
<td></td>
</tr>
<tr>
<td>E: emma.neal@allisonworldwide.com</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong><em>媒体 – 澳大利亚</em></strong></td>
<td></td>
</tr>
<tr>
<td>BlueDot Media</td>
<td></td>
</tr>
<tr>
<td>Steve Dabkowski</td>
<td></td>
</tr>
<tr>
<td>T: +61 419 880 486</td>
<td></td>
</tr>
<tr>
<td>E: steve@bluedot.net.au</td>
<td></td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU1UY3pOQ00zTWpreE1qQTJJekl3TVRjME16ST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5MTczNCM3MjkxMjA2IzIwMTc0MzI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTNjOWI5NmYtZWMxOC00MjMxLTg2ZjMtODY0ZGM2MDNhZjQyLTEwMjkwMDUtMjAyNS0xMS0yNC1lbg==/tiny/Mesoblast-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/ZTNjOWI5NmYtZWMxOC00MjMxLTg2ZjMtODY0ZGM2MDNhZjQyLTEwMjkwMDUtMjAyNS0xMS0yNC1lbg==/tiny/Mesoblast-Limited.png"/></p>

在年度股东大会上，Mesoblast 的交易更新强调了 Ryoncil®收入的持续强劲增长 | MESO 股票新闻